Thermo Fisher Completes One Lambda Purchase | GenomeWeb

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has completed its acquisition of transplant diagnostics firm One Lambda for $925 million.

One Lambda, which had 2011 revenues of around $182 million, will become part of Thermo Fisher's Specialty Diagnostics Segment. The Canoga Park, Calif.-based firm develops tests that are used by transplant centers for tissue typing, mainly for determining compatibility between donors and recipients and for detecting the presence of antibodies that can result in transplant rejection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.